Global Briefs: Bavarian Nordic & Civica

A roundup of news from Bavarian Nordic and Civica. Highlights below.

* Bavarian Nordic To Supply Smallpox Vaccine for Monkeypox
* Civica Names New CEO

Bavarian Nordic To Supply Smallpox Vaccine for Monkeypox
Bavarian Nordic, a Kvistgaard, Denmark-based a vaccine developer and manufacturer, has secured a contract with an undisclosed European country to supply its smallpox vaccine, Imvanex, in response to new cases of monkeypox evolving during May 2022.

The first European case of monkeypox was confirmed on May 7, 2022, in an individual who returned from travel to Nigeria, where monkeypox is endemic. Subsequently, more cases have been confirmed across England, Portugal, and Spain, with additional suspected cases currently being investigated globally, including in the US.

Bavarian Nordic’s smallpox vaccine is approved in the US as Jynneos and in Canada as Imvamune, both places with the approval extended to cover the monkeypox indication. The vaccine is approved in Europe as Imvanex for only the smallpox indication but has previously been provided for off-label use in response to monkeypox cases.

Source: Bavarian Nordic

Civica Names New CEO
Civica, a non-profit pharmaceutical company providing generics and drugs in shortage, has announced that Ned McCoy, currently Civica’s Chief Operating Officer, will succeed Martin VanTrieste as Civica’s President and Chief Executive Officer, effective June 1, 2022.

Mr. VanTrieste will remain an advisor to the company and continue serving on Civica’s Board of Directors. As part of this transition, Mr. McCoy will also join the Civica Board of Directors on June 1, 2022.

Mr. McCoy has provided oversight for Civica’s manufacturing efforts, including the building of Civica’s essential medicines manufacturing facility in Petersburg, Virginia, expected to be operational in early 2024. McCoy has led efforts to secure manufacturing partnerships for over 60 sterile injectable medications. Most recently, Mr. McCoy was involved in the partnership with Civica’s insulin development partner, GeneSys Biologics, a Hyderabad, India-based clinical-stage bio/pharmaceutical company, with the plan to bring Civica biosimilar insulins to market beginning in 2024.

Prior to Civica, Mr. McCoy served at Abbott for 32 years, where he led teams in hospital products, pharmaceutical products (now AbbVie), nutrition and corporate mergers and acquisitions.

Source: Civica